• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional non pharmacological treatment for depression and medications do not work for many patients suffering from depression treatment free. Personalized treatment could be the answer.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into personalised micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to discover their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only half of those who have the condition receive treatment1. In order to improve outcomes, what is the best treatment for anxiety and depression healthcare professionals must be able to identify and treat patients who have the highest chance of responding to specific treatments.

Personalized depression treatment is one method of doing this. Utilizing sensors on mobile phones and an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to discover the biological and behavioral predictors of response.

To date, the majority of research on predictors for depression treatment effectiveness has focused on clinical and sociodemographic characteristics. These include demographics like age, gender, and education, as well as clinical aspects such as symptom severity and comorbidities as well as biological markers.

A few studies have utilized longitudinal data in order to determine mood among individuals. A few studies also take into account the fact that moods can vary significantly between individuals. Therefore, it is essential to develop methods that allow for the identification of individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify various patterns of behavior and emotion that vary between individuals.

In addition to these modalities, the team developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm integrates the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was correlated with CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was not strong, however (Pearson r = 0,08, P-value adjusted for BH = 3.55 10 03) and varied significantly among individuals.

Predictors of symptoms

Depression is the leading reason for disability across the world, but it is often not properly diagnosed and treated. In addition an absence of effective treatments and stigmatization associated with depressive disorders stop many individuals from seeking help.

To facilitate personalized treatment, identifying patterns that can predict symptoms is essential. However, the methods used to predict symptoms depend on the clinical interview which is unreliable and only detects a limited number of symptoms that are associated with depression.2

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to capture a large number of distinct actions and behaviors that are difficult to document through interviews, and also allow for continuous and high-resolution measurements.

The study included University of California Los Angeles students with moderate to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment according to the severity of their depression. Patients who scored high on the CAT DI of 35 or 65 students were assigned online support by the help of a coach. Those with a score 75 patients were referred to psychotherapy in person.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial characteristics. The questions covered age, sex, and education and financial status, marital status and whether they were divorced or not, their current suicidal thoughts, intentions or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted every other week for participants who received online support and once a week for those receiving in-person treatment.

Predictors of Treatment Response

A customized treatment for depression is currently a top research topic and many studies aim at identifying predictors that will help clinicians determine the most effective medications for each individual. Pharmacogenetics, in particular, is a method of identifying genetic variations that affect how to treatment depression the human body metabolizes drugs. This allows doctors to select drugs that are likely to work best for each patient, while minimizing the time and effort required in trials and errors, while avoid any adverse effects that could otherwise slow advancement.

Another promising approach is to create predictive models that incorporate the clinical data with neural imaging data. These models can then be used to determine the most appropriate combination of variables predictors of a specific outcome, such as whether or not a drug will improve mood and symptoms. These models can be used to determine the patient's response to a treatment they are currently receiving, allowing doctors to maximize the effectiveness of the treatment currently being administered.

A new generation of studies utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been shown to be effective in predicting treatment outcomes, such as response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to be the norm in future treatment.

Research into depression's underlying mechanisms continues, in addition to ML-based predictive models. Recent research suggests that the disorder is connected with neural dysfunctions that affect specific circuits. This suggests that an individualized depression treatment will be based on targeted therapies that target these circuits to restore normal functioning.

One method to achieve this is through internet-delivered interventions that can provide a more personalized and customized experience for patients. One study found that an internet-based program helped improve symptoms and provided a better quality life for MDD patients. A controlled, randomized study of a customized treatment for depression revealed that a significant number of patients saw improvement over time as well as fewer side consequences.

Predictors of Side Effects

In the treatment of depression, the biggest challenge is predicting and determining the antidepressant that will cause minimal or zero side effects. Many patients take a trial-and-error approach, using a variety of medications prescribed until they find one that is safe and effective. Pharmacogenetics offers a new and exciting method to choose antidepressant medicines that are more effective and precise.

Many predictors can be used to determine which antidepressant to prescribe, such as gene variants, patient phenotypes (e.g. gender, sex or ethnicity) and comorbidities. To identify the most reliable and reliable predictors of a specific treatment, randomized controlled trials with larger samples will be required. This is because the identifying of interaction effects or moderators may be much more difficult in trials that consider a single episode of treatment per participant, rather than multiple episodes of treatment over time.

In addition to that, predicting a patient's reaction will likely require information about the comorbidities, symptoms profiles and the patient's own experience of tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables are believed to be correlated with the severity of MDD, such as age, gender, race/ethnicity and SES BMI and the presence of alexithymia and the severity of depression symptoms.

The application of pharmacogenetics to depression treatment is still in its beginning stages and there are many obstacles to overcome. First is a thorough understanding of the underlying genetic mechanisms is essential as well as a clear definition of what is the best treatment for anxiety and depression (Dokuwiki.stream) constitutes a reliable predictor for treatment response. Ethics such as privacy and the ethical use of genetic information should also be considered. The use of pharmacogenetics may eventually reduce stigma associated with mental health treatment and improve the outcomes of treatment. But, like all approaches to psychiatry, careful consideration and application is essential. At present, the most effective option is to offer patients an array of effective depression treatment guidelines medication options and encourage them to talk with their physicians about their experiences and concerns.